ClinicalTrials.gg
CompletedNCT01752855Updated Oct 29, 2014Results posted

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

A Phase 2 interventional study of New formulation adalimumab in Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 20 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-29.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
56th of 87
88 · median 160
Started
2012
with 3 others
Phase 2
9 of 87
2 open now
Registered
50th of 87
by date
Lead sponsor
7 of 87
AbbVie (prior sponsor, Abbott)

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 56th largest by enrollment, is one of 4 that started in 2012, is one of 9 in phase 2, and was the 50th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

A Phase 2b, open-label extension (OLE) study in rheumatoid arthritis (RA) patients designed to collect long-term safety, tolerability, efficacy, and immunogenicity data of the proposed new adalimumab formulation.

Read the detailed description

All participants who completed Study NCT01712178 had an opportunity to enroll into the study and to receive the new adalimumab formulation at a dose of 40 mg every other week (eow) for an additional 24 weeks.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has completed the preceding Study M13-390 for rheumatoid arthritis and has not developed any discontinuation criteria from that study.
  2. If female, subject is either not of , defined as for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy) or is of childbearing potential and is practicing an approved method of throughout the study and for 150 days after last dose of study drug. Examples of approved methods of birth control include the following (see local for more detail):

    • Condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD);
    • Hormonal contraceptives for 90 days prior to study drug administration;
    • A vasectomized partner.
  3. Subjects must be able and willing to self-administer subcutaneous (SC) injections or have a qualified person available to administer SC injections.
  4. Subject is judged to be in good general health as determined by the Principal Investigator based upon the results of medical history, physical examination, laboratory profile performed at Baseline.
  5. Subjects must be able and willing to provide written informed consent and to comply with the requirements of this study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Ongoing infections at Week 0 that have NOT been successfully treated. Subjects with ongoing infections undergoing treatment may be enrolled BUT NOT dosed until the infection has been successfully treated.
  2. Subject currently uses or plans to use anti-retroviral therapy at any time during the study.
  3. Subject plans to use any during the study.
  4. Positive pregnancy test at Baseline (Week 0).
  5. Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    New formulation of adalimumab 40 mg every other week

    New formulation adalimumab 40 mg every other week

    Biological: New formulation adalimumab

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Weeks 36 and 48

    The Disease Activity Score (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

    Time frame: Baseline (Study NCT01712178 Week 0 Visit), Weeks 36 and 48

  2. Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Weeks 36 and 48

    American College of Rheumatology 20% (ACR20) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))

    Time frame: Baseline (Study NCT01712178 Week 0 Visit), Weeks 36 and 48

  3. Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Weeks 36 and 48

    American College of Rheumatology 50% (ACR50) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))

    Time frame: Baseline (Study NCT01712178 Week 0 Visit), Weeks 36 and 48

  4. Mean Change From Baseline in Health Assessment Questionnaire (HAQ-DI) at Weeks 36 and 48

    The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is 0.22. HAQ remission indicating normal physical function is defined by HAQ-DI \< 0.5.

    Time frame: Baseline (Study NCT01712178 Week 0 Visit), Weeks 36 and 48

Secondary outcomes

  1. Percentage of Participants Positive for Anti-adalimumab Antibody

    Percentage of participants with anti-adalimumab antibody

    Time frame: Week 24 through Week 48

07

Results

Posted Oct 29, 2014

Participant flow

Participant flow — Overall Study
MilestoneNew Formulation for 48 WeeksCurrent Formulation for 24 Weeks, New Formulation for 24 Weeks
Started4444
Completed4340
Not completed14
Withdrew: Adverse event10
Withdrew: Withdrew consent02
Withdrew: Lack of efficacy02

Outcome measures

PrimaryMean Change From Baseline in Disease Activity Score 28 (DAS28) at Weeks 36 and 48

The Disease Activity Score (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C-reactive protein, and general health are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Time frame:
Baseline (Study NCT01712178 Week 0 Visit), Weeks 36 and 48
Reported as:
Mean · units on a scale
Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Weeks 36 and 48
units on a scaleNew Formulation for 48 WeeksCurrent Formulation for 24 Weeks, New Formulation for 24 Weeks
Week 36-2.4 ± 1.17-2.2 ± 1.05
Week 48-2.4 ± 1.29-2.2 ± 1.28
PrimaryPercentage of Participants With an American College of Rheumatology (ACR) 20 Response at Weeks 36 and 48

American College of Rheumatology 20% (ACR20) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))

Time frame:
Baseline (Study NCT01712178 Week 0 Visit), Weeks 36 and 48
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Weeks 36 and 48
percentage of participantsNew Formulation for 48 WeeksCurrent Formulation for 24 Weeks, New Formulation for 24 Weeks
Week 3672.776.7
Week 4874.480.0
PrimaryPercentage of Participants With an American College of Rheumatology (ACR) 50 Response at Weeks 36 and 48

American College of Rheumatology 50% (ACR50) response. A participant is a responder if the following 3 criteria for improvement from baseline are met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Disability Index of the Health Assessment * CRP (Acute phase reactant (Erythrocyte sedimentation rate/C-reactive protein))

Time frame:
Baseline (Study NCT01712178 Week 0 Visit), Weeks 36 and 48
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Weeks 36 and 48
percentage of participantsNew Formulation for 48 WeeksCurrent Formulation for 24 Weeks, New Formulation for 24 Weeks
Week 3650.051.2
Week 4853.557.5
PrimaryMean Change From Baseline in Health Assessment Questionnaire (HAQ-DI) at Weeks 36 and 48

The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is 0.22. HAQ remission indicating normal physical function is defined by HAQ-DI \< 0.5.

Time frame:
Baseline (Study NCT01712178 Week 0 Visit), Weeks 36 and 48
Reported as:
Mean · units on a scale
Mean Change From Baseline in Health Assessment Questionnaire (HAQ-DI) at Weeks 36 and 48
units on a scaleNew Formulation for 48 WeeksCurrent Formulation for 24 Weeks, New Formulation for 24 Weeks
Week 36-0.5 ± 0.60-0.5 ± 0.69
Week 48-0.5 ± 0.57-0.5 ± 0.58
SecondaryPercentage of Participants Positive for Anti-adalimumab Antibody

Percentage of participants with anti-adalimumab antibody

Time frame:
Week 24 through Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Positive for Anti-adalimumab Antibody
percentage of participantsNew Formulation for 48 WeeksCurrent Formulation for 24 Weeks, New Formulation for 24 Weeks
Percentage of Participants Positive for Anti-adalimumab Antibody13.618.2

Adverse events

Collected over Adverse events were collected from the time of study drug administration until 70 days following the last dose, approximately 58 weeks. Serious adverse events were collected from the time the participant signed the informed consent.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
New Formulation for 48 Weeks—2/44 (4.5%)18/44 (40.9%)
Current Formulation for 24 Weeks, New Formulation for 24 Weeks—1/44 (2.3%)19/44 (43.2%)
Most frequent serious events
Most frequent serious events
EventNew Formulation for 48 WeeksCurrent Formulation for 24 Weeks, New Formulation for 24 Weeks
IRON DEFICIENCY ANAEMIABlood and lymphatic system disorders1/440/44
ATRIAL FIBRILLATIONCardiac disorders1/440/44
OSTEOARTHRITISMusculoskeletal and connective tissue disorders1/441/44
Most frequent other events
Most frequent other events
EventNew Formulation for 48 WeeksCurrent Formulation for 24 Weeks, New Formulation for 24 Weeks
NASOPHARYNGITISInfections and infestations6/447/44
CYSTITISInfections and infestations4/442/44
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations4/444/44
RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders3/444/44
DYSPEPSIAGastrointestinal disorders3/443/44
ORAL HERPESInfections and infestations3/442/44
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations2/443/44
BACK PAINMusculoskeletal and connective tissue disorders0/443/44
HEADACHENervous system disorders3/443/44

Baseline characteristics

All participants who received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)New Formulation for 48 WeeksCurrent Formulation for 24 Weeks, New Formulation for 24 WeeksTotal
Mean55.7 ± 10.852.0 ± 12.053.9 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)New Formulation for 48 WeeksCurrent Formulation for 24 Weeks, New Formulation for 24 WeeksTotal
Female373774
Male7714
08

Study locations

20 sites
  • Site Reference ID/Investigator# 92113
    Mesa, Arizona 85202, United States
  • Site Reference ID/Investigator# 92118
    Hemet, California 92543, United States
  • Site Reference ID/Investigator# 92117
    Wichita, Kansas 67203, United States
  • Site Reference ID/Investigator# 92115
    Clifton, New Jersey 07012, United States
  • Site Reference ID/Investigator# 92116
    Philadelphia, Pennsylvania 19152, United States
  • Site Reference ID/Investigator# 92114
    Charleston, South Carolina 29406, United States
  • Site Reference ID/Investigator# 92053
    Brussels, 1200, Belgium
  • Site Reference ID/Investigator# 92054
    Liege, 4000, Belgium
  • Site Reference ID/Investigator# 91954
    Brno, 638 00, Czech Republic
  • Site Reference ID/Investigator# 91955
    Prague 2, 128 50, Czech Republic
  • Site Reference ID/Investigator# 91953
    Uherske Hradiste, 686 01, Czech Republic
  • Site Reference ID/Investigator# 91956
    Zlin, 760 01, Czech Republic
  • Site Reference ID/Investigator# 92073
    Ratingen, 40882, Germany
  • Site Reference ID/Investigator# 92074
    Vega Baja, 00693, Puerto Rico
  • Site Reference ID/Investigator# 92093
    Bucharest, 020475, Romania
  • Site Reference ID/Investigator# 92095
    Cluj-Napoca, 400006, Romania
  • Site Reference ID/Investigator# 92094
    Ploiesti, 100337, Romania
  • Site Reference ID/Investigator# 92096
    Banska Bystrica, 97405, Slovakia
  • Site Reference ID/Investigator# 92097
    Senica, 905 01, Slovakia
  • Site Reference ID/Investigator# 92098
    Zilina, 010 01, Slovakia
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2012
First posted
Dec 19, 2012
Start
Dec 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Oct 29, 2014
Last update
Oct 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01752855
Responsible party
Sponsor
First posted
Dec 19, 2012
Start date
Dec 2012
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Oct 29, 2014
Last update
Oct 29, 2014

Study contacts

Andy Payne, PhD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion